Developer docs
API playgroundTry for free, no card

Search company profiles

RxBiologics

Full company profile

uuid003b4e2

Namestring
RxBiologics
Legal namestring
RxBiologics Ltd
Websiteurl
rxbiologics.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

RxBiologics is a UK-based contract research organisation providing antibody discovery services to pharmaceutical, biotechnology, and academic clients. The company operates from the Babraham Research Campus in Cambridge as a wholly-owned subsidiary of RxCelerate, the drug discovery and development services group founded in 2013, and was itself established in 2018 when RxCelerate partnered with biotech entrepreneur and antibody engineer Jonny Finlay to commercialise the proprietary Galaxy® antibody library platform.

The Galaxy® platform is the company's central technology asset. It is a fully human antibody phage display library constructed using 'smart randomness' for targeted diversification, 'Glass Spleen' B cell-like evolution to access relevant antibody space without excessive mutational load, and controlled light chain diversity for predictable outcomes. The platform is offered on a license-free open access basis, which is positioned as a key differentiator against incumbent display-based CROs. Service offerings span antibody discovery, lead isolation (including high-throughput screening, flow cytometry, and NGS-based diversity interrogation), antibody profiling (ELISA, SPR, BLI, polyreactivity, AC-SINS, functional assays), immune library generation, antibody humanisation and optimisation, in silico analysis, reagent generation, and rapid common light chain bispecifics generation. The Scientific Advisory Board includes co-inventor of clinical-phase antibodies Jonny Finlay and Greg Carven, inventor of pembrolizumab (Keytruda).

The business model is professional services revenue: bespoke, contract-based discovery programmes priced on tailored workflows and deliverables, with no publicly disclosed pricing. Go-to-market is direct, sales-led engagement with enterprise pharmaceutical and biotech clients globally, supported by organic digital presence on LinkedIn, Twitter/X, and YouTube, plus direct email and phone contact. RxBiologics leverages RxCelerate's broader drug discovery infrastructure (biology, in-silico design, chemistry, programme management) to deliver end-to-end preclinical biologics programmes. The company has not raised outside venture capital and is privately held.

Short descriptiontext

RxBiologics is a UK-based antibody discovery CRO offering bespoke services built on its proprietary Galaxy® human antibody library platform, serving pharmaceutical, biotechnology, and academic clients from Cambridge as a subsidiary of RxCelerate.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody discovery services, phage display technology, biologics drug discovery, bispecific antibodies, contract research organization
Industry1 code
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biologics Drug Discovery Services (Contract Research)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Bespoke CRO services for biologics drug discovery, providing comprehensive work packages from early discovery through preclinical phases. Services include antibody discovery, production, profiling, and humanization delivered on a project/contract basis tailored to client specifications.

rxbiologics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

RxBiologics operates as a contract research organization (CRO) providing bespoke antibody discovery services built around its proprietary Galaxy® human antibody library platform, which is based on human antibody phage display technology. The company delivers comprehensive biologics drug discovery work packages — including antibody discovery, lead isolation, antibody profiling, immune library generation, antibody humanisation, in silico analysis, reagent generation, and rapid bispecifics generation — to pharmaceutical, biotech and academic clients, supporting programs from early discovery through preclinical phases.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

RxBiologics is a biologics drug discovery services company offering a platform-plus-services model built around its proprietary Galaxy® antibody library technology. The Galaxy® Platform serves as the core technology, with services including antibody discovery, lead isolation, antibody profiling, immune library generation, antibody humanisation and optimisation, in silico antibody analysis, reagent generation, and rapid bispecifics generation. Services support biologics drug discovery from early discovery through preclinical phases, with the Galaxy® Library enabling delivery of clinic-ready antibodies with drug-like properties in a single-pass process.

Product and service9 records
1Galaxy® Antibody Library Platform
CategoryCore platform technology
Description

Proprietary human antibody library technology based on human antibody phage display, using smart randomness and Glass Spleen B-cell-like evolution to generate fully human, highly specific, functional and stable antibodies with drug-like properties in a single pass. Provided on a license-free open access basis to clients and partners.

2Antibody Discovery Services
CategoryCRO service
Description

Comprehensive antibody discovery service using the proprietary Galaxy® Library to screen antibodies with desired specificity and cross-reactivity. Delivered to pharmaceutical, biotech and academic clients as part of bespoke antibody discovery programs.

3Lead Isolation
CategoryCRO service
Description

High-throughput screening service including biochemical assay formats for binding and inhibition, flow cytometry cell-binding analysis, comprehensive sequence analysis, and NGS-based diversity interrogation to identify lead antibody candidates.

4Antibody Profiling
CategoryCRO service
Description

Comprehensive profiling service including ELISA, flow cytometry cell binding, SPR affinity measurement, BLI epitope binning, polyreactivity, AC-SINS, functional assays and biophysical analysis of antibody candidates.

5Immune Library Generation
CategoryCRO service
Description

Custom build of antibody libraries from immune repertoires for standard and domain antibodies, integrated into the platform drug discovery process to support bespoke antibody programs.

6Antibody Humanisation and Optimisation
CategoryCRO service
Description

Humanisation and deimmunisation within CDR regions using in silico design and display technology approaches to generate optimal antibody sequences for therapeutic development.

7In Silico Antibody Analysis
CategoryCRO service
Description

Computational services including modelling, structure prediction, developability prediction, immunogenicity prediction, antibody optimisation and humanisation, delivered using licensed in silico software tools.

8Reagent Generation
CategoryCRO service
Description

Licensed mammalian cell line services for custom antibody and antigen production, protein purification and QC, and transient cell expression for screening and profiling of antibody reagents.

9Rapid Bispecifics Generation
CategoryCRO service
Description

Common light chain bispecific antibody generation capability enabling rapid and cost-effective production of bispecific antibodies without special engineering requirements.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

RxCelerate is the parent company of RxBiologics, providing fully integrated or standalone drug discovery and development services for small molecules and biologics. RxBiologics leverages RxCelerate's biology, in-silico design, chemistry, and programme management capabilities to deliver comprehensive biologics drug discovery programmes from early discovery through preclinical phases. RxCelerate was founded in 2013.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GenScript offers antibody discovery services alongside biologics CDMO capabilities, targeting the same pharma/biotech customer base seeking end-to-end biologics development support.

TypeBroad incumbent
Description

WuXi Biologics is a global CRDMO offering antibody discovery, cell line development, and manufacturing services, representing a large-scale competitor for outsourced biologics programs.

TypeDirect peer
Description

Adimab operates a proprietary yeast-display antibody discovery platform offering outsourced discovery services to pharma and biotech, with a similar platform-plus-services model and 'right first time' ethos.

TypeBroad incumbent
Description

Eurofins Discovery provides a broad portfolio of CRO services including antibody generation, screening, and characterization, offering comparable antibody discovery capabilities as part of a wider scientific services platform.

TypeBroad incumbent
Description

Lonza is a global CDMO with biologics discovery and manufacturing services, offering overlapping antibody discovery capabilities as part of a much larger integrated service portfolio to enterprise pharma clients.

TypeDirect peer
Description

BioInvent is a clinical-stage biotech with a proprietary antibody library platform (n-CoDeR) and offers antibody discovery and development services comparable to RxBiologics' offering.

TypeEmerging player
Description

Trianni offered transgenic mouse antibody discovery platforms competing with phage-display-based approaches; now part of AbCellera, representing an alternative discovery modality in the same market segment.

TypeBroad incumbent
Description

Charles River is a large CRO with biologics discovery and development services through its CDMO and discovery segments, competing for similar pharma/biotech contracts at greater scale.

TypeDirect peer
Description

ImmunoPrecise provides antibody discovery and characterization services using multiple platforms (phage display, B-cell, hybridoma), serving pharma and biotech clients similar to RxBiologics' customer base.

TypeDirect peer
Description

AbCellera is a leading antibody discovery CRO that uses single B-cell screening plus AI/ML to deliver fully human antibodies to pharma partners, directly competing for outsourced biologics discovery programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RxBiologics

Biologics Drug Discovery Services (Contract Research)rxbiologics.com

RxBiologics is a UK-based antibody discovery CRO offering bespoke services built on its proprietary Galaxy® human antibody library platform, serving pharmaceutical, biotechnology, and academic clients from Cambridge as a subsidiary of RxCelerate.

What RxBiologics does

RxBiologics is a UK-based contract research organisation providing antibody discovery services to pharmaceutical, biotechnology, and academic clients. The company operates from the Babraham Research Campus in Cambridge as a wholly-owned subsidiary of RxCelerate, the drug discovery and development services group founded in 2013, and was itself established in 2018 when RxCelerate partnered with biotech entrepreneur and antibody engineer Jonny Finlay to commercialise the proprietary Galaxy® antibody library platform.

The Galaxy® platform is the company's central technology asset. It is a fully human antibody phage display library constructed using 'smart randomness' for targeted diversification, 'Glass Spleen' B cell-like evolution to access relevant antibody space without excessive mutational load, and controlled light chain diversity for predictable outcomes. The platform is offered on a license-free open access basis, which is positioned as a key differentiator against incumbent display-based CROs. Service offerings span antibody discovery, lead isolation (including high-throughput screening, flow cytometry, and NGS-based diversity interrogation), antibody profiling (ELISA, SPR, BLI, polyreactivity, AC-SINS, functional assays), immune library generation, antibody humanisation and optimisation, in silico analysis, reagent generation, and rapid common light chain bispecifics generation. The Scientific Advisory Board includes co-inventor of clinical-phase antibodies Jonny Finlay and Greg Carven, inventor of pembrolizumab (Keytruda).

The business model is professional services revenue: bespoke, contract-based discovery programmes priced on tailored workflows and deliverables, with no publicly disclosed pricing. Go-to-market is direct, sales-led engagement with enterprise pharmaceutical and biotech clients globally, supported by organic digital presence on LinkedIn, Twitter/X, and YouTube, plus direct email and phone contact. RxBiologics leverages RxCelerate's broader drug discovery infrastructure (biology, in-silico design, chemistry, programme management) to deliver end-to-end preclinical biologics programmes. The company has not raised outside venture capital and is privately held.

RxBiologics firmographics

Firmographics
Name
RxBiologics
Legal name
RxBiologics Ltd
Website
https://rxbiologics.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
RxBiologics is a UK-based antibody discovery CRO offering bespoke services built on its proprietary Galaxy® human antibody library platform, serving pharmaceutical, biotechnology, and academic clients from Cambridge as a subsidiary of RxCelerate.
Ownership category
akta.pro rank

RxBiologics industry classification

Industry
Product category
Biologics Drug Discovery Services (Contract Research)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)

Keywords

  • Antibody discovery services
  • Phage display technology
  • Biologics drug discovery
  • Bispecific antibodies
  • Contract research organization

Where RxBiologics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

RxBiologics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Contract Research Services: Bespoke CRO services for biologics drug discovery, providing comprehensive work packages from early discovery through preclinical phases. Services include antibody discovery, production, profiling, and humanization delivered on a project/contract basis tailored to client specifications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

RxBiologics product offering

Product offering

Core offering

RxBiologics operates as a contract research organization (CRO) providing bespoke antibody discovery services built around its proprietary Galaxy® human antibody library platform, which is based on human antibody phage display technology. The company delivers comprehensive biologics drug discovery work packages — including antibody discovery, lead isolation, antibody profiling, immune library generation, antibody humanisation, in silico analysis, reagent generation, and rapid bispecifics generation — to pharmaceutical, biotech and academic clients, supporting programs from early discovery through preclinical phases.

Product overview

RxBiologics is a biologics drug discovery services company offering a platform-plus-services model built around its proprietary Galaxy® antibody library technology. The Galaxy® Platform serves as the core technology, with services including antibody discovery, lead isolation, antibody profiling, immune library generation, antibody humanisation and optimisation, in silico antibody analysis, reagent generation, and rapid bispecifics generation. Services support biologics drug discovery from early discovery through preclinical phases, with the Galaxy® Library enabling delivery of clinic-ready antibodies with drug-like properties in a single-pass process.

Differentiator

Problem solved

Functional benefit

Products and services

  • Galaxy® Antibody Library Platform Proprietary human antibody library technology based on human antibody phage display, using smart randomness and Glass Spleen B-cell-like evolution to generate fully human, highly specific, functional and stable antibodies with drug-like properties in a single pass. Provided on a license-free open access basis to clients and partners.
  • Antibody Discovery Services Comprehensive antibody discovery service using the proprietary Galaxy® Library to screen antibodies with desired specificity and cross-reactivity. Delivered to pharmaceutical, biotech and academic clients as part of bespoke antibody discovery programs.
  • Lead Isolation High-throughput screening service including biochemical assay formats for binding and inhibition, flow cytometry cell-binding analysis, comprehensive sequence analysis, and NGS-based diversity interrogation to identify lead antibody candidates.
  • Antibody Profiling Comprehensive profiling service including ELISA, flow cytometry cell binding, SPR affinity measurement, BLI epitope binning, polyreactivity, AC-SINS, functional assays and biophysical analysis of antibody candidates.
  • Immune Library Generation Custom build of antibody libraries from immune repertoires for standard and domain antibodies, integrated into the platform drug discovery process to support bespoke antibody programs.
  • Antibody Humanisation and Optimisation Humanisation and deimmunisation within CDR regions using in silico design and display technology approaches to generate optimal antibody sequences for therapeutic development.
  • In Silico Antibody Analysis Computational services including modelling, structure prediction, developability prediction, immunogenicity prediction, antibody optimisation and humanisation, delivered using licensed in silico software tools.
  • Reagent Generation Licensed mammalian cell line services for custom antibody and antigen production, protein purification and QC, and transient cell expression for screening and profiling of antibody reagents.
  • Rapid Bispecifics Generation Common light chain bispecific antibody generation capability enabling rapid and cost-effective production of bispecific antibodies without special engineering requirements.

Companies that use RxBiologics

Customer profile

Segments3 records

Ideal customer profiles3 records

RxBiologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

RxBiologics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • RxCeleratecoreStrategic or Co-development PartnerRxCelerate is the parent company of RxBiologics, providing fully integrated or standalone drug discovery and development services for small molecules and biologics. RxBiologics leverages RxCelerate's biology, in-silico design, chemistry, and programme management capabilities to deliver comprehensive biologics drug discovery programmes from early discovery through preclinical phases. RxCelerate was founded in 2013.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

RxBiologics competitors and assessment

Company assessment

Direct peers

  • GenScript ProBio: GenScript offers antibody discovery services alongside biologics CDMO capabilities, targeting the same pharma/biotech customer base seeking end-to-end biologics development support.
  • Adimab: Adimab operates a proprietary yeast-display antibody discovery platform offering outsourced discovery services to pharma and biotech, with a similar platform-plus-services model and 'right first time' ethos.
  • BioInvent International: BioInvent is a clinical-stage biotech with a proprietary antibody library platform (n-CoDeR) and offers antibody discovery and development services comparable to RxBiologics' offering.
  • ImmunoPrecise Antibodies: ImmunoPrecise provides antibody discovery and characterization services using multiple platforms (phage display, B-cell, hybridoma), serving pharma and biotech clients similar to RxBiologics' customer base.
  • AbCellera: AbCellera is a leading antibody discovery CRO that uses single B-cell screening plus AI/ML to deliver fully human antibodies to pharma partners, directly competing for outsourced biologics discovery programs.

Broad incumbents

  • WuXi Biologics: WuXi Biologics is a global CRDMO offering antibody discovery, cell line development, and manufacturing services, representing a large-scale competitor for outsourced biologics programs.
  • Eurofins Discovery: Eurofins Discovery provides a broad portfolio of CRO services including antibody generation, screening, and characterization, offering comparable antibody discovery capabilities as part of a wider scientific services platform.
  • Lonza Biologics: Lonza is a global CDMO with biologics discovery and manufacturing services, offering overlapping antibody discovery capabilities as part of a much larger integrated service portfolio to enterprise pharma clients.
  • Charles River Laboratories: Charles River is a large CRO with biologics discovery and development services through its CDMO and discovery segments, competing for similar pharma/biotech contracts at greater scale.

Emerging players

  • Trianni (acquired by AbCellera): Trianni offered transgenic mouse antibody discovery platforms competing with phage-display-based approaches; now part of AbCellera, representing an alternative discovery modality in the same market segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

RxBiologics social profiles

Digital presence

RxBiologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RxBiologics leadership team

Management profile

Number of profiles

Profiles6 records

RxBiologics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RxBiologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RxBiologics

What does RxBiologics do?

RxBiologics operates as a contract research organization (CRO) providing bespoke antibody discovery services built around its proprietary Galaxy® human antibody library platform, which is based on human antibody phage display technology. The company delivers comprehensive biologics drug discovery work packages — including antibody discovery, lead isolation, antibody profiling, immune library generation, antibody humanisation, in silico analysis, reagent generation, and rapid bispecifics generation — to pharmaceutical, biotech and academic clients, supporting programs from early discovery through preclinical phases.

Is RxBiologics a public or private company?

RxBiologics is a private company. It is classified as corporate owned and is currently operating.

When was RxBiologics founded?

RxBiologics was founded in 2018. It employs 11 to 50 people.

Where is RxBiologics based?

RxBiologics is headquartered in Cambridge, United Kingdom, in the Europe region.

How does RxBiologics make money?

One revenue line is on record: contract Research Services.

Who are RxBiologics's main competitors?

Direct peers on record are GenScript ProBio, Adimab, BioInvent International, ImmunoPrecise Antibodies and AbCellera. Broad incumbents are WuXi Biologics, Eurofins Discovery, Lonza Biologics and Charles River Laboratories. Trianni (acquired by AbCellera) is listed as an emerging player.

Does RxBiologics have an API?

No public API is recorded for RxBiologics.

What industry is RxBiologics in?

RxBiologics's product category is Biologics Drug Discovery Services (Contract Research). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales